Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ADAG
- Company Adagene Inc.
- Price $2.01
- Changes Percentage 10.44
- Change 0.19
- Day Low $1.65
- Day High $2.02
- Year High $4.85
- Year Low $1.3
- Market Cap $112,192,822
- Price Avg 50 EMA (D) $3.64
- Price Avg 200 EMA (D) $3.31
- Exchange NASDAQ
- Volume 317,022
- Average Volume 271,871
- Open $1.82
- Previous Close $1.82
- EPS -0.38
- PE -7.90
- Earnings Announcement 2027-03-31 12:00:00
- Shares Outstanding $37,648,598
Company brief: ADAGENE INC. (ADAG )
- Healthcare
- Biotechnology
- Dr. Peter P. Luo Ph.D.
- https://www.adagene.com
- CN
- N/A
- 02-09-2021
- US0053291078
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
